Zentalis Pharmaceuticals News and Activities

Zentalis Pharmaceuticals is a company listed under the stock ticker ZNTL (US).

View the org chart displaying its 16 main executives

Most searched biographies at Zentalis Pharmaceuticals

• Julie Eastland, Chief Executive Officer, President and Director
• Luke Walker, Director
• Enoch Kariuki, Director

Popular executive movements at Zentalis Pharmaceuticals

• Sarah Kelly has joined the company as Senior Vice President of Commercial Strategy  (posted on May 28 2026).
• Shannon Campbell has joined the company as Director  (posted on May 28 2026).
• Karan Takhar, Director, has left the company  (posted on December 18 2025).

Create your alert
to follow the executive moves at Zentalis Pharmaceuticals.

Zentalis Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Zentalis Pharmaceuticals

• Press Releases | Zentalis Pharmaceuticals
• Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference | Zentalis Pharmaceuticals
• Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
• View more press releases Close

Social media about Zentalis Pharmaceuticals

• Zentalis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Zentalis Pharmaceuticals on LinkedIn, X (Twitter) & YouTube